NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks
27 Feb

NovoCure (NVCR) reported $161.27 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 20.6%. EPS of -$0.61 for the same period compares to -$0.45 a year ago.

The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $161.3 million. With the consensus EPS estimate being -$0.34, the EPS surprise was -79.41%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how NovoCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net revenues- United States: $107.20 million versus $99.85 million estimated by two analysts on average.
  • Net revenues- International markets - Total: $52.09 million versus $53.62 million estimated by two analysts on average.
  • Net revenues- Greater China: $1.98 million versus $3.45 million estimated by two analysts on average.
  • Net revenues- Japan: $8.51 million compared to the $8.45 million average estimate based on two analysts.
View all Key Company Metrics for NovoCure here>>>

Shares of NovoCure have returned -14% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NovoCure Limited (NVCR) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10